Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENTPD1 | P49961 | 1/20 | 0.67 |
| ▸ | ENTPD2 | Q9Y5L3 | 3/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 12/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 12/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 11/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13210937 | 0.92 | ENTPD2 (0.66) | ENTPD1ENTPD2ADORA3ADORA1ADORA2B | |
| SCHEMBL13210940 | 0.87 | ENTPD2 (0.56) | ENTPD1ENTPD2ADORA3ADORA1ADORA2B | |
| SCHEMBL13210954 | 0.84 | ENTPD1 (0.61) | ENTPD1ENTPD2ADORA3ADORA1ADORA2B | |
| SCHEMBL13210931 | 0.82 | ENTPD2 (0.63) | ENTPD1ENTPD2 | |
| SCHEMBL13210974 | 0.80 | ENTPD1 (1.00) | ENTPD1ENTPD2 | |
| SCHEMBL13210958 | 0.80 | ENTPD2 (0.66) | ENTPD1ENTPD2ADORA3ADORA1ADORA2B | |
| SCHEMBL13210932 | 0.80 | ENTPD2 (0.61) | ENTPD1ENTPD2ADORA3ADORA1ADORA2B | |
| SCHEMBL13210943 | 0.80 | ENTPD2 (0.63) | ENTPD1ENTPD2ADORA3ADORA1ADORA2B | |
| SCHEMBL13210938 | 0.80 | ENTPD2 (0.52) | ENTPD1ENTPD2ADORA3ADORA1ADORA2B | |
| SCHEMBL13210935 | 0.78 | ENTPD2 (0.41) | ENTPD1ENTPD2ADORA3ADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204182-A1 | ECTONUCLEOTIDASE INHIBITORS | RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONN (DE) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204182-A1 | ECTONUCLEOTIDASE INHIBITORS | NT5E, NT5C2, ENTPD1 | ENTPD1 3/4885ENTPD2 10/4885ADORA3 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.